15/11/2024 17:11

Healius (HLS) $1.335

HLS -16.04%: When it rains, it pours! HLS today provided commentary at their AGM via the CEO’s presentation that was disappointing, insofar as while they said that pathology volumes have increased by 4.5% for the year to date, with revenues growing by 5.9%, they put a big caveat on how that revenue would translate into earnings due to cash draw from investments and inflationary pressures, in terms of goods and labour.

Read more

16/10/2024 09:24

Healius Ltd (HLS) $1.85

Pathology giant HLS surged +7.25% on Tuesday, making it the top performer on the main board. In the process, it posted fresh 12-month highs - yet interestingly, no news was crossing the wires. Analysts dislike this company as they did the resources before China fuelled a strong short covering rally: 4 Sells & 6 Holds with an average price target (PT) of $1.55, well below yesterday's close – this data can be seen on the MM website.

Read more

23/09/2024 16:52

Healius (HLS) $1.73

HLS +7.45% was up nicely today on news it has agreed to sell its imaging unit Lumus to U.S-based Affinity Equity Group for $965 million. As per our last note on HLS, we expected a sale price of circa. $700 million. We think this is a good price given Lumus has been loss-making for the past 2 years.

Read more

06/09/2024 17:00

Healius (HLS) $1.65

HLS -2.65% was hit hard early today, down as much as 9% at the lows before recovering. The drop was a result of Barrenjoey downgrading the stock to sell with a $1.37 price target, a bearish view that is actually aligned with the majority in the market i.e. more analysts have a negative outlook on HLS.

Read more

02/09/2024 09:57

Active Growth Portfolio – Amendments

We are making two changes to the Active Growth Portfolio.

Read more

22/08/2024 09:24

Healius Ltd (HLS) $1.66

HLS soared +12.9% on Wednesday following its FY24 result, which beat the average analyst estimates. Margin improvements caught the eye, plus the potential for some value accretive asset sales.

Read more

01/03/2024 09:30

Healius Ltd (HLS) $1.11

One of the positive aspects that shone through this reporting season has been the ability of companies to reduce costs to maintain profits as top-line growth becomes harder. This flexibility was enhanced through COVID, where companies had to be incredibly nibble as many watched sales plummet overnight. The opposite is true at Helius, with COVID testing volumes a huge win for their pathology business, underpinning a significant uplift in sales.

Read more

21/11/2023 09:25

Healius Ltd (HLS) $1.83

HLS is looking to raise $187mn through a rights issue at $1.20, a steep 34.6% discount to the stock's last trade on Friday – they needed the cash! The offer was on a 1-for-3.65 basis, with the freshly listed equity looking to list under a separate ticker code as its suitor, Australian Clinical Labs (ACL), still has its scrip-only offer open.

Read more

27/10/2023 09:06

Healius Ltd (HLS) $1.93

HLS is testing its 2020 lows as debt levels weigh on investor sentiment. e.g. on June 30th, their gearing ratio was at 3.48x, still below the latest increased 4.0x covenant agreed with bankers. At the start of the month, we wrote, “We think HLS is residing in the “if in doubt, stay out” category as long-dated yields rise at a time when their debt levels are simply too high, the stock has subsequently fallen -11% but nothing’s changed.

Read more

05/10/2023 09:01

Healius Ltd (HLS) $2.17

HLS fell another -1.4% yesterday, taking the stock down towards its COVID lows, debt levels are likely to be weighing on investor sentiment – on June 30th, their gearing ratio was at 3.48x, below the latest increased 4.0x covenant agreed with bankers.

Read more